MeiraGTx Holdings plc has recently released its 10-K report, offering insight into the company's financial condition and ...

The venture aims to advance MeiraGTx’s Parkinson’s gene therapy through Phase III trials with up to $430m in funding from ...

BofA analyst Alec Stranahan raised the firm’s price target on MeiraGTx (MGTX) to $14 from $12 and keeps a Buy rating on the shares, citing a ...

Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Meiragtx Holdings (MGTX – Research Report) today and set a price ...

MeiraGTx (Nasdaq: MGTX) has entered into a strategic partnership with artificial intelligence firm Hologen to accelerate the ...

The joint venture with generative AI firm Hologen hands MeiraGTx $200 million up front as well as other financial perks — a ...

UiPath Inc. PATH was down, falling 16% to $10.00 after the company reported a fourth-quarter revenue miss and issued ...

Hologen is paying MeiraGTx $200 million upfront and committing $230 million to fund Hologen Neuro AI and a Parkinson's disease gene therapy.

With MeiraGTx eyeing up how to take the drug through phase 3 and onto commercialization, Hologen has stepped in. The ...

Joint venture, Hologen Neuro AI, will expedite Phase 3 development of AAV-GAD for Parkinson’s Disease and industrialize ...

MeiraGTx and Hologen form a neuro-AI drug development joint venture, with up to $430M in funding to advance Parkinson's and CNS treatments.

MeiraGTx (MGTX) stock gains as the company teams up with Hologen to form a JV to advance gene therapies for Parkinson's and other CNS diseases. Read more here.